Stockwinners Market Radar for February 01, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:22 EST Cathie Wood's ARK Investment bought 63K shares of Twilio today

19:22 EST Mesoblast names Dr. Eric Rose as Chief Medical Officer - Mesoblast Limited announces the appointment of Dr. Eric Rose as the company's Chief Medical Officer. Dr. Rose has been a non-executive director of Mesoblast since 2013.

18:47 EST Brunswick CEO: We have tremendous growth levers - In an interview on CNBC's Mad Money, David Foulkes said Brunswick's engine business has gained a tremendous amount of market share over the past year. He expects the company to produce 20% topline growth in 2022. Overall, he sees $10B in annual revenue in 2025. Foulkes said Brunswick has been more successful in attracting people to the boat industry than its competitors.

18:21 EST Microsoft director Emma Walmsley buys $1.0M in common stock - In a regulatory filing, Microsoft disclosed that its director Emma Walmsley bought 3.3K shares of common stock on January 29th in a total transaction size of $1.0M.

17:58 EST Alphabet Class A expects strong pace of hiring to continue in 2022 - Expects to continue to lead in search quality. Says will continue to execute share repurchase plan.

17:40 EST CVB Financial approves 10M share repurchase program - CVB Financial announced that the Board of Directors authorized the company to repurchase up to 10M shares of the company's common stock including by means of an initial accelerated share repurchase agreement involving $70M of the company's common stock and one or more Rule 10b5-1 plans or other appropriate buy-back arrangements, including open market purchases and private transactions.

17:30 EST Alphabet Class A says will continue to invest in AI technologies - Says seeing "exciting momentum" at YouTube; more people creating content than ever before. Says Cloud business grew 45% y/y in Q4. Says partner ecosystem accelerating Cloud growth. Plans to continue to "aggressively invest" in Cloud. Says had "terrific quarter" in retail. Says continues to generate strong free cash flow. Says expense growth largely due to headcount. Expects "meaningful increase" in CapEx in 2022. Comments taken from Q4 earnings conference call.

17:29 EST Starbucks backs FY22 global SSS growth view of high single digits - Says most China stores had restrictions exiting Q1. Says number of global markets saw sustained growth in Q1. Says inflation at "highest level in decades." Sees 200 basis points of incremental margin pressure in FY22.

17:23 EST Electronic Arts says launch of "Battlefield 2042" did not meet expectations - Says EA player network has grown to more than 540M unique active accounts over the last year. Says more than 180M monthly active accounts on average engaged in games during FY22. Says "Apex Legends" monthly active users were up more than 30% year-over-year. Says FY22 biggest year yet for "Apex Legends". Says net bookings in EA Sports portfolio up 10%. Says "Battlefield 2042" experienced unanticipated performance issues. Says made meaningful updates to game and will continue to do so. Says expects mobile to be growth catalyst in FY23. Comments taken from Q3 earnings conference call.

17:17 EST L3Harris Technologies awarded $117.25M Air Force contract modification - L3Harris Technologies has been awarded a $117.25M contract modification to a previously awarded contract for Period Three system sustainment services. Work is expected to be completed by January 31, 2023. FY22 operations and maintenance funds in the amount of $14.53M are being obligated at the time of award. The total cumulative face value of the contract is $493.14M. The Space Systems Center Directorate of Contracting is the contracting activity.

17:11 EST General Motors says will not resume common stock dividend at this time

17:10 EST Siemens awarded $225.5M Army contract for COVID-19 tests - Siemens was awarded a $225.5M firm-fixed-price contract for rapid antigen-based diagnostic tests for COVID-19. Bids were solicited via the internet with one received. Work will be performed in Tarrytown, New York, with an estimated completion date of March 18. FY22 American Rescue Plan Act funds in the amount of $225.5M were obligated at the time of the award. U.S. Army Contracting Command is the contracting activity.

17:09 EST General Motors CEO says planning to invest in 3rd EV truck plan - Says company has delivered a key milestone on the drive to commercialization - to commercialize Cruise rideshare service. of EV capacity in North America by the end of 2025. Says to announce location of 4th U.S. cell plant in the first half of the year. Says pulling significant investment into FY22-FY25 timeframe. Comments taken from Q4 earnings conference call.

17:01 EST Seanergy Marine gets Nasdaq listing compliance notice - Seanergy Maritime "announced that it has received written notification from The Nasdaq Stock Market dated January 26, 2022, indicating that because the closing bid price of the Company's common stock for 30 consecutive business days, from December 13, 2021 to January 25, 2022, was below the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2). Pursuant to the Nasdaq Listing Rule 5810(c)(3)(A), the applicable grace period to regain compliance is 180 days, or until July 25, 2022."

16:58 EST General Motors sees FY22 adjusted EBIT $13B-$15B vs. $14.3B in FY21

16:55 EST Electric Last Mile Solutions trading halted, news pending

16:35 EST Sportsman's Warehouse appoints Jeff White CFO - Sportsman's Warehouse Holdings announced the appointment of Jeff White as their Chief Financial Officer, effective January 21. Mr. White will oversee all financial aspects of the Company including, financial planning and analysis, accounting and financial reporting, tax, internal audit, investor relations, treasury, and risk management.

16:33 EST Hershey to report in three segments - The Hershey announced it is transitioning from two reportable segments, "North America" and "International and Other", to the following three reportable segments: the North America Confectionery segment is responsible for chocolate and nonchocolate confectionery market position in the U.S. and Canada. The North America Salty Snacks segment is responsible for salty snacking products in the U.S. International segment is a combination of all other operating segments that are not individually material, including those geographic regions where we operate outside of North America. The company will begin providing financial results through the three new reportable segments with its Q4 and FY21 results, scheduled to be announced on Thursday morning, February 3rd.

16:33 EST Regeneron, Sanofi to report positive Dupixent data at AAAAI meeting - Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced positive Dupixent data across five diseases with underlying type 2 inflammation will be presented at the American Academy of Allergy, Asthma and Immunology Annual Meeting from February 25-28. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis and atopic dermatitis. Additionally, positive results from two Phase 3 trials in a sixth indication, prurigo nodularis, were recently announced and will be presented at a separate medical meeting later this year. New pivotal data showing significant disease improvements in EoE and CSU will be presented for the first time. The use of Dupixent in these diseases is currently under clinical investigation and its safety and efficacy have not been fully evaluated by any regulatory authority.

16:29 EST Terex announces Series B investment in Viatec - Terex announced its Series B investment in Viatec, a South Carolina-based manufacturer of plug-and-play electronic power take-off systems that support electrification of utility fleets. Terex is the lead investor in the Series B investment round along with other participants including Duke Energy. In conjunction with this investment, a Terex representative will fill one of five seats on Viatec's board.

16:23 EST Alphabet Class A shares up 7% to $2,934 after Q4 earnings beat

16:21 EST MDU Resources' WBI Energy puts North Bakken Expansion project into service - WBI Energy, a subsidiary of MDU Resources Group, put the North Bakken Expansion project into service after completing construction and testing on the natural gas pipeline. The expansion has capacity to transport 250M cubic feet of natural gas per day from the Bakken production area in North Dakota, with the potential to be increased up to 625M cubic feet per day through additional compression if needed to meet growing customer demand. As part of the project, WBI Energy and its main contractor, Michels Corp., completed a 15,426-foot horizontal directional drill of a 24-inch pipeline crossing Lake Sakakawea on the Missouri River in North Dakota. The crossing of just less than 3 miles is one of the longest of its kind.

16:19 EST PayPal sees FY22 TPVs reaching $1.5T - TPV expected to grow 19%-22% at currrent spot rates and 21%-23% on an FXN basis.

16:17 EST Transcat sees Q4 Service revenue growth in high teens - CEO Lee D. Rudow says: "We have a strong balance sheet, sustainable Service segment gross margins and an active M&A pipeline. We are confident that the strength of our unique and enhanced value proposition and our new customer pipeline positions us well for continued strong organic growth. For the fourth quarter of fiscal 2022, which is historically the strongest quarter of our fiscal year due to the seasonality of our Service business, we expect Service revenue growth to be in the high-teens. We expect Service gross margin to be in the range of 35% as we benefit from a seasonally higher level of volume. Distribution revenue is expected to grow high single-digits in the fourth quarter. Total operating expenses are expected to increase approximately $0.5 million sequentially from the third quarter and will include expenses associated with our recent acquisition of Tangent Labs."

16:14 EST Amdocs, Samsung to collaborate to deliver private network solutions - Samsung Electronics America and Amdocs announced the companies will collaborate to deliver end-to-end 4G and 5G private network solutions to U.S. enterprises to help businesses across key industries leverage next-generation communications applications and services. The agreement includes delivery of Samsung's complete set of private network solutions.

16:12 EST Becton Dickinson board approves Embecta spinoff - BD announced its board of directors has approved the planned spinoff of its diabetes care business, which will be known as Embecta Corp. and declared a pro rata distribution of all of the outstanding shares of embecta common stock to BD shareholders. The board voted unanimously to approve the spinoff to occur on April 1, 2022, concluding that the separation of the diabetes care business from the rest of BD is consistent with BD's growth strategy and helps to sharpen its focus on its core innovation priorities. The separation will also enhance the ability of embecta to attract capital investment, recruit talent and allocate resources and efforts into its unique business development, innovation and product development programs to drive future growth, which ultimately benefits more people living with diabetes around the world. Upon completion of the distribution, embecta will be an independent, publicly traded company focused on diabetes management, and BD will retain no ownership interest. embecta has applied to have its common stock listed on NASDAQ under the ticker symbol EMBC and expects its stock will begin trading on a "regular way" basis on April 1.

16:11 EST Alphabet declares 20-for-one stock split - Alphabet announced that the board of directors had approved and declared a 20-for-one stock split in the form of a one-time special stock dividend on each share of the Company's Class A, Class B, and Class C stock. The stock split is subject to stockholder approval of an amendment to the company's Amended and Restated Certificate of Incorporation to increase the number of authorized shares of Class A, Class B, and Class C stock to accommodate the stock split. If approval is obtained, each of the company's stockholders of record at the close of business on July 1, 2022, the record date, will receive, after the close of business on July 15, a dividend of 19 additional shares of the same class of stock for every share held by such stockholder as of the record date.

16:10 EST ICF International awarded $30M contract by Con Edison - Con Edison of New York has recently selected global consulting and digital services provider ICF for a recompete contract to manage and significantly expand implementation of its residential energy efficiency portfolio. The contract has a ceiling value of over $30M. ICF will continue to implement Con Edison's residential energy efficiency portfolio and other programs, providing a full suite of services including program delivery, engineering, marketing, information technology, customer care and incentive processing. This includes implementing the utility's New York State Clean Heat decarbonization program as well as a new weatherization component.

16:09 EST Alphabet CEO highlights 'ongoing strong growth' in ad business in Q4 - Sundar Pichai, CEO of Alphabet and Google, said: "Our deep investment in AI technologies continues to drive extraordinary and helpful experiences for people and businesses, across our most important products. Q4 saw ongoing strong growth in our advertising business, which helped millions of businesses thrive and find new customers, a quarterly sales record for our Pixel phones despite supply constraints, and our Cloud business continuing to grow strongly."

16:08 EST Aclaris Therapeutics names James Loerop as Chief Business Officer - Aclaris Therapeutics announced the appointment of James Loerop as Chief Business Officer, effective January 31.

16:08 EST Alphabet reports Q4 Google Cloud revenue $5.54B vs. $3.83B a year ago

16:08 EST Alphabet reports Q4 Google advertising revenue $61.24B vs. $46.2B a year ago - Reports Q4 YouTube ads revenue $8.63B vs. $6.89B in same quarter of prior year. Reports Q4 Google Search and other revenue $43.3B vs. $31.9B a year ago.

16:06 EST Fortune Brands acquires Solar Innovations for $63M - Fortune Brands Home & Security "announced it has acquired Solar Innovations, LLC, a leading producer of wide-opening exterior door systems and outdoor enclosures. Solar Innovations will be part of Fortune Brands' Outdoors & Security business segment. Its complementary product offerings will support the segment's outdoor living strategy and help Fortune Brands to further capitalize on the attractive outdoor living space and outdoor living trends. The Company completed the acquisition on January 31, 2022, for a price, net of tax benefits, of up to $63M."

16:05 EST CyrusOne holders approve acquisition by KKR - CyrusOne announced its stockholders approved the previously announced merger pursuant to which funds managed by KKR, a leading global investment firm, and Global Infrastructure Partners, one of the world's leading infrastructure investors, will acquire all outstanding shares of common stock of the Company. At a virtual special meeting held today, the proposal to approve the merger, the merger agreement and the other transactions contemplated by the merger agreement was approved by 78.41% of the common stock outstanding and entitled to vote, and more than 99.5% of the votes cast. Upon the closing of the merger, each issued and outstanding share of common stock of the Company will be converted into the right to receive $90.50 in cash in a transaction valued at approximately $15 billion, including the assumption of debt.

14:49 EST Subaru reports January U.S. sales down 4.8% to 44,158 vehicles - Subaru of America, a wholly owned subsidiary of Subaru Corporation of Japan, reported 44,158 vehicle sales for January, a 4.8% decrease compared with 46,400 in January 2021. "Like much of the automotive industry, SOA continues to face production challenges because of the semiconductor shortage and supply chain issues," the company stated.

13:28 EST Williams raises quarterly dividend 3.7% to 42.5c per share - Williams' board of directors has approved a regular dividend of 42.5c per share, or $1.70 annualized, on the company's common stock, payable on March 28, 2022, to holders of record at the close of business on March 11, 2022. This is a 3.7% increase from Williams' first-quarter 2021 quarterly dividend of 41c per share, paid in March 2021.

12:45 EST Cedar Fair trading resumes

12:34 EST 22nd Century supports upcoming FDA action on menthol ban - 22nd Century Group announced its continued support for a menthol ban in nicotine laden combustible cigarettes following FDA's expectation to publish proposed rules in April 2022. On January 27, 2022, the FDA posted an update on its FDA Voices site stating that it "remains on track" with its plans to prohibit menthol in combustible tobacco products. "We fully support the FDA taking action on menthol cigarettes, in particular due to the disproportionate impact highly addictive traditional menthol cigarettes have on minority communities," said James Mish, CEO. "We believe FDA's reduced harm commitment and rule-making process could leave VLN Menthol King as the only menthol cigarette on the market due to its 95% reduction in nicotine. Maintaining access to a non-addictive menthol cigarette such as VLN Menthol King that 'Helps You Smoke Less' is a critical off-ramp for current menthol smokers. By providing a non-addictive menthol option, we believe FDA's policy can help menthol smokers truly move away from addictive nicotine products rather than merely transitioning to another addictive combustible cigarette or nicotine product," continued Mish. The FDA authorized 22nd Century's VLN reduced nicotine content cigarette products on December 23, 2021. In its MRTP authorization press release, the FDA acknowledged its menthol plans, stating "In reaching today's determination, the FDA considered both the current legal status of menthol cigarettes and the available science demonstrating that these particular products could help addicted cigarette smokers reduce their nicotine consumption and the number of cigarettes they smoke per day. The FDA is committed to moving forward with the rulemaking process to ban menthol as a characterizing flavor in cigarettes and all characterizing flavors in cigars and remains on track to issue proposed rules in the spring of 2022."

12:24 EST JetBlue pilots announce intention to open contract negotiations - The JetBlue Master Executive Council of the Air Line Pilots Association, Int'l announced to JetBlue Airways management its intention to open contract negotiations 180 days in advance of their collective bargaining agreement's July 31, 2022, amendable date. "As we begin to emerge from one of the most difficult times in the history of the commercial aviation industry, JetBlue Airways has demonstrated enormous resilience-thanks in no small part to the efforts of its pilots," said Capt. Chris Kenney, JetBlue MEC chair. "Those efforts should be recognized by our next contract, and we're eager to have productive discussions with JetBlue management as part of the negotiating process." The current CBA was the first with a unionized employee group at JetBlue and came after more than three years of negotiations. The CBA included pay improvements and job protections long sought by the pilot group. "Our Negotiating Committee stands ready to work with JetBlue management on our next contract so that JetBlue's growth and expansion can continue with the support of a fairly compensated pilot group and by recognizing their professionalism and contributions to the airline's success," continued Capt. Kenney.

12:22 EST Interactive Brokers reports January DARTs down 20% y/y - Interactive Brokers Group reported its Electronic Brokerage monthly performance metrics for January. Brokerage highlights for the month included: 2.621 million Daily Average Revenue Trades, 20% lower than prior year and 18% higher than prior month. Ending client equity of $352.5B, 12% higher than prior year and 6% lower than prior month. Ending client margin loan balances of $50.1B, 23% higher than prior year and 8% lower than prior month. Ending client credit balances of $89.3B, including $2.3Bin insured bank deposit sweeps, 8% higher than prior year and 3% higher than prior month. 1.73M client accounts, 45% higher than prior year and 3% higher than prior month. 344 annualized average cleared DARTs per client account. Average commission per cleared Commissionable Order of $2.47 including exchange, clearing and regulatory fees.

12:03 EST M.D.C. Holdings falls -9.4% - M.D.C. Holdings is down -9.4%, or -$4.78 to $45.91.

12:02 EST Pitney Bowes falls -15.9% - Pitney Bowes is down -15.9%, or -98c to $5.18.

12:01 EST IBM acquires Sentaca, terms not disclosed - IBM announced it has acquired Sentaca, a telco consulting services and solutions provider. The acquisition will accelerate IBM's hybrid cloud consulting business, adding critical skills to help communications service providers and media giants modernize on multiple cloud platforms, innovate, and transform their businesses. Headquartered in Boston, Massachusetts, Sentaca's team of highly experienced technology consultants across the U.S. and Canada build and migrate mission-critical applications on leading cloud service providers and open-source platforms like Red Hat OpenShift and OpenStack. Sentaca has supported digital transformation, next-generation networks and improved consumer experience for CSPs and media companies since its founding in 2008. Sentaca will join IBM Consulting's fast-growing Hybrid Cloud Services business to solve clients' strategic and technology challenges such as cost-of-ownership, monetization, scalable and secure architecture, and address opportunities including 5G, IoT and streaming that can accelerate the creation and delivery of new services. Sentaca's domain expertise, assets and client relationships will help IBM meet industry demand and strengthen its position as a prime systems integrator for the emerging network and 5G market. This acquisition closed on January 31, 2022. Financial details were not disclosed.

12:00 EST UPS rises 15.1% - UPS is up 15.1%, or $30.46 to $232.67.

11:37 EST StarTek names Bharat Rao as global CEO, Ronald Gillette as strategic advisor - Startek announced the appointments of Bharat Rao as Global CEO and Ronald Gillette as Strategic Advisor and Head of Business Transformation. Appointed president in October 2021, Rao will immediately begin transitioning into the Global CEO role. Rao continues to serve as a Director on the boards of Startek and CCC, a joint venture based in the Middle East. As Strategic Advisor and Head of Business Transformation, Gillette will advise Startek and its Board as a Senior Advisor.

11:12 EST Cedar Fair trading resumes

11:06 EST Cedar Fair trading halted, volatility trading pause

10:15 EST Mazda reports January North America sales down 16.5% to 21,079 vehicles - Mazda North American Operations reported total January sales of 21,079 vehicles, a decrease of 16.5% compared to January 2021. Mazda Canada reported January sales of 3,493 vehicles, a decrease of 13.5% compared to January last year. Mazda Motor de Mexico reported January sales of 3,474 vehicles, a decrease of 7.8% compared to January last year.

10:04 EST Oscar Health, Centrum collaborate to expand access in Miami-Dade County - Centrum Health and Oscar Health announced a collaboration that will expand access for Oscar's Individual & Family plan members in Miami-Dade County.

10:01 EST LoanDepot falls -11.5% - LoanDepot is down -11.5%, or -54c to $4.15.

10:00 EST Pitney Bowes falls -19.3% - Pitney Bowes is down -19.3%, or -$1.19 to $4.97.

10:00 EST Helix Energy rises 9.3% - Helix Energy is up 9.3%, or 33c to $3.86.

09:53 EST AMTD International Inc - ADR trading resumes

09:47 EST Kemper falls -11.5% - Kemper is down -11.5%, or -$6.88 to $53.10.

09:47 EST Pitney Bowes falls -15.4% - Pitney Bowes is down -15.4%, or -95c to $5.21.

09:47 EST AMC Entertainment rises 10.5% - AMC Entertainment is up 10.5%, or $1.68 to $17.74.

09:46 EST Cross Country Education acquires Selected, terms not disclosed - Cross Country Education, a division of Cross Country Healthcare, has acquired substantially all the assets of Selected, a cloud-based matching and hiring talent platform that pairs educators with schools based on mutually shared preferences to ensure a tailored and long-term fit. Terms of the transaction were not disclosed.

09:32 EST Inpixon secures contract for hybrid event solution - Inpixon announced it has secured an agreement to provide its hybrid event solution to support a hybrid conference to be hosted by a leading Fortune 500 company anticipated to have more than 50,000 attendees. The solution will power simultaneous delivery of event content and services to both a custom-branded, location-aware mobile app for in-person attendees and multi-language virtual event platform for remote attendees.

09:27 EST AMTD International Inc - ADR trading halted, news pending

09:19 EST Qualigen Therapeutics engages Stephen Neidle as scientific advisor - Qualigen Therapeutics announced that it has engaged Professor Stephen Neidle as a scientific advisor. Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company's in-licensed genomic quadruplex-selective transcription inhibitor platform. Qualigen is developing this platform's lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma, which represents the vast majority of pancreatic cancers. Qualigen's in-licensed QN-302 program was developed by Professor Neidle and his team from the UCL School of Pharmacy, in Great Britain, one of the top ten pharmacy and pharmacology research institutions in the world. Professor Neidle has a distinguished 30+ year history in nucleic acid research and drug design with over 500 published papers and 14 patents.

09:18 EST Tyler Technologies extends contract for digital government services with Hawaii - Tyler Technologies announced the state of Hawaii signed a contract extension for Tyler's digital government and payments services. The three-year agreement expands upon a 21-year relationship between the state and Tyler subsidiary, NIC.

09:17 EST Synaptogenix announces peer-reviewed article on Bryostatin - Synaptogenix announced that its peer-reviewed scientific manuscript entitled, "Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease, or AD, in the Absence of Memantine" was published in the Journal of Alzheimer's Disease. The article documents evidence from two placebo-controlled trials that Bryostatin-1 improved cognition over baseline of advanced AD patients. "Rigorous statistical analyses, including a pooled testing of identical pre-specified cohorts in two separate trials, revealed highly significant benefit of Bryostatin-1 treatment of AD patients in the absence of the dementia treatment memantine. Blinded placebo controls in these trials allow for the exclusion of the placebo effects that so often accompany early testing of candidate drugs to treat AD," stated Daniel Alkon, President and Chief Scientific Officer. "Importantly, we believe that the peer-reviewed data in our manuscript has provided additional justification for our continued grant support from the National Institutes of Health for our ongoing Phase 2b clinical trial."

09:12 EST Creative Realities and Reflect Systems awarded $10M contract - Creative Realities and Reflect Systems announced that their first joint sales effort has resulted in a project to deploy digital experiences for a retail customer at hundreds of locations nationwide for an expected total contract value in excess of $10M. The large-scale project comes shortly after CRI and Reflect announced in November their plans to merge, bringing together two of the industry's leading companies to form one, operating under CRI's name and Rick Mills' leadership, CRI's current CEO. The retail customer is the first of many wins expected for the combined company that will boast the most complete, competitive digital signage offerings on the market.

09:11 EST UPS received 11.7% of total revenue from Amazon in 2021

09:09 EST PHI Group, Sundial Renewables sign cooperation agreement - PHI Group is pleased to announce that CO2-1-0 has signed an Memorandum of Understanding with Canada-based SUNDIAL RENEWABLES CORP. to cooperate in a new disruptive carbon mitigation program through worldwide environmentally sustainable projects. According to the Agreement, SUNDIAL and CO2-1-0 will cooperate in acquiring carbon credits from solar power, wind power, biomass, and other renewable energy projects and developments as facilitated, managed, invested, owned and operated by SUNDIAL. Carbon credits will be digitalized into Carbon Tokens using blockchain-crypto technology and deploying IoT.

09:08 EST FuboTV,NBCUniversal in multi-platform content pact for XXIV Olympic Winter Games - fuboTV in agreement with NBCUniversal, announced a multi-platform content offering for NBCUniversal's coverage of the XXIV Olympic Winter Games from Beijing, China, which take place from February 2-20, 2022. fuboTV's subscribers will have access to NBCUniversal's Winter Olympics-record 2,800+ hours of Olympic programming, including coverage of all competition sessions, live and on-demand. In addition to enjoying extensive linear coverage on the networks of NBCUniversal, including NBC, USA Network, and CNBC, subscribers can stay connected to the Olympic Winter Games wherever they go via NBCOlympics.com and the NBC Sports app, via authentication, which will stream more than 2,100 hours of Winter Olympics coverage. The following multi-platform offerings from NBCUniversal will allow fuboTV subscribers to watch and be a part of the Winter Olympics through their televisions, PCs, mobile and tablet apps, and connected TVs.

09:07 EST U.S. Steel names Daniel Brown COO - United States Steel announced that Daniel Brown has been named senior VP of advanced technology steelmaking and COO of Big River Steel Works. In this role he will be responsible for flat roll steel production currently in place and planned in Arkansas utilizing Electric Arc Furnaces, Endless Strip Production, electrical steel and advanced finishing facilities. Brown previously held the position of VP. The change is effective February 1. Brown will continue to report to president and CEO David Burritt.

09:06 EST Petco and Rover Group announce collaboration agreement - Petco Health and Wellness Company (WOOF) announced a new initiative with Rover.com (ROVR) to connect Petco customers to pet sitting, boarding and dog walking services. The partnership between the two pet industry leaders expands on Petco's unique, end-to-end ecosystem of health and wellness offerings - including pet products, training, grooming and veterinary care - by making it easier for customers to access services for dogs and cats on Rover directly from petco.com. Those who book for the first time can receive a one-time $10 discount. Additionally, members of Petco's Vital Care offering, a paid annual program providing pet parents with a comprehensive wellness plan that makes it easier and more affordable to care for pets' whole health, will receive a one-time discount of $20 on their booking beginning in the Spring of 2022.

09:05 EST MarketAxess announces Chief Information Officer succession - MarketAxess (MKTX) announced that Nash Panchal will succeed Nick Themelis as MarketAxess' Chief Information Officer. MarketAxess previously announced Themelis' retirement from MarketAxess, after 16 years as the company's Chief Information Officer. Panchal will join MarketAxess in March after more than 20 years at Goldman Sachs (GS). Themelis will remain with the company in an advisory capacity through 2022 to ensure a smooth transition.

09:04 EST ResMed appoints Urvashi Tyagi as Chief Technology Officer - ResMed announced the appointment of Urvashi Tyagi as chief technology officer, CTO, effective today. As CTO, Tyagi will lead ResMed's Digital Health Technology team. Before joining ResMed, Tyagi was chief technology officer and senior vice president for ADP. With Tyagi's hire, previous CTO and current SaaS President Bobby Ghoshal now transitions full-time into leading ResMed's SaaS business.

09:03 EST Nucor to invest $290M to modernize Indiana sheet mill - Nucor announced that its board of directors has approved a $290M investment to expand the product capabilities of its Crawfordsville, Indiana steel sheet mill by adding a construction grade continuous galvanizing line and prepaint line. This investment will create 80 jobs and is expected to take two years to complete pending permitting, regulatory approvals, the award of state and local incentives and other tax considerations. The construction grade continuous galvanizing line will have a capacity of 300,000 tons per year while the prepaint line will have an annual capacity of 250,000 tons per year. This investment further expands Nucor's existing galvanizing and prepaint capabilities, which include recently added continuous galvanizing lines at its sheet mills in Arkansas and Kentucky, and the acquisition of a prepaint line at its Arkansas sheet mill. Nucor Steel Indiana employs approximately 770 teammates.

09:01 EST UPS sees domestic operating margin expanding 50bps in 2022 - Sees domestic revenue growth around 5.5% in 2022. Sees international revenue growth 7.7% for 2022. Expects international demand-related surcharges to remain elevated in 2022. Sees $17B in supply chain solutions revenue in 2022.

08:59 EST Domino's Pizza to pay carryout customers who order online a $3 tip - Domino's Pizza said Monday that carryout customers who order online can claim a $3 tip to use on their next online carryout order. "It takes skill to get pizza from a Domino's store to your door," said Art D'Elia, Domino's executive president - chief marketing officer. "As a reward, Domino's is giving a $3 tip to online carryout customers who take the time and energy out of their day to act as their own delivery drivers. After all, we think they deserve it." Carryout customers who order online now through May 22, 2022, are eligible to claim the $3 coupon code, Domino's said.

08:57 EST MicroStrategy acquired 660 more bitcoins for $25M in cash - MicroStrategy disclosed that during the period between December 30, 2021 and January 31, 2022, it purchased approximately 660 bitcoins for approximately $25M in cash, at an average price of approximately $37,865 per bitcoin, inclusive of fees and expenses. As of January 31, 2022, the company held approximately 125,051 bitcoins that were acquired at an aggregate purchase price of $3.78B and an average purchase price of approximately $30,200 per bitcoin, inclusive of fees and expenses.

08:49 EST SurgePays issues letter to shareholders on 2022 expectations - SurgePays issued a letter to shareholders from its Chairman & CEO, Brian Cox, summarizing initial expectations for 2022. "With the company's foundation solidified, the balance sheet improved and the product offering growing, we anticipate a return to revenue growth in 2022. Specific goals include: As I mentioned earlier, we have a goal of 200,000 mobile broadband subscriber activations by the end of the year. We believe we can generate revenue of at least $75M in 2022. This is only for Mobile Broadband Subscribers recurring monthly revenue- a channel that only started in August of 2021. We expect SurgePays consolidated to hit $130M in annualized revenues by Q4 in 2022... We believe we will be offering service in over 40 states by April 2022 thus enabling us to calibrate sales upward with an essentially unlimited geographic landscape for sales. We expect to grow the network of stores transacting on our SurgePays fintech platform organically and through additional acquisitions. The immediate focus is building the national sales team... Now, we can bring on stores rapidly with our key objective simply being adding stores daily. One of our key business metrics and overall valuation targets will specifically be how many independently owned stores are transacting on our network. Our ability to sell Bitcoin for cash, at the community store level, should start gaining traction and market acceptance as we believe we will be on the forefront of digital currently adoption by the underbanked. This is especially true in the immigrant market once consumers realize they can avoid the 15%-18% fees they are paying remittance companies simply to send cash back home to Central and South America... SurgePays is positioned to be the company at the grass roots store level in the U.S. enabling this disruptive transition."

08:49 EST GSK's ViiV Healthcare announces FDA approval of Cabenuva label expansion - ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline (GSK) with Pfizer (PFE) and Shionogi Limited (SGIOY) as shareholders, announced that the U.S. Food and Drug Administration approved Cabenuva for every-two-month dosing for the treatment of HIV-1 in virologically suppressed adults on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Cabenuva is "the first and only complete long-acting HIV treatment regimen" and was first approved by the U.S. FDA in January 2021 as a once-monthly treatment for HIV-1 in virologically suppressed adults. It contains ViiV Healthcare's cabotegravir extended-release injectable suspension in a single-dose vial and rilpivirine extended-release injectable suspension in a single-dose vial, a product of Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). The U.S. FDA approval allows Cabenuva to be dosed monthly or every two months. Lynn Baxter, Head of North America at ViiV Healthcare, said: "ViiV Healthcare is pleased to continue our leadership in researching and developing long-acting innovative HIV treatment options that address the evolving needs of the HIV community. Today's approval is a remarkable achievement given where HIV treatment was just a decade ago. We know some people living with HIV struggle with taking daily oral pills, and Cabenuva may allow them to maintain viral suppression while significantly reducing dosing to as few as six times a year."

08:49 EST Jaguar Health, Napo Pharmaceuticals complete crofelemer in vitro study - Jaguar Health and Napo Pharmaceuticals announced the completion of a third-party, investigator-initiated preclinical enterocyte in vitro study to evaluate the effects of crofelemer, Napo Pharmaceuticals' plant-based prescription drug, on certain genetic defects that result in specific forms of congenital diarrheal disorders. Jaguar Health believes that these study results will support certain requests received from the office of orphan products development at the FDA in response to the orphan drug designation application Napo Pharmaceuticals filed with the FDA for crofelemer for congenital diarrheal disorders in infants and children.

08:47 EST UPS expects 2022 to be another challenging year

08:42 EST Diana Shipping announces time charter contract for M/V Los Angeles - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Koch Shipping Pte. Ltd., Singapore, for one of its Newcastlemax dry bulk vessels, the m/v Los Angeles. The gross charter rate is $26,250 per day, minus a 5% commission paid to third parties, for a period until minimum January 15, 2023 up to maximum March 15, 2023. The charter commenced retroactively as of January 30, 2022. The m/v Los Angeles was chartered, as previously announced, to Engelhart CTP Freight SA, at a gross charter rate of $14,250 per day, minus a 5% commission paid to third parties. The "Los Angeles" is a 206,104 dwt Newcastlemax dry bulk vessel built in 2012. The employment of "Los Angeles" is anticipated to generate approximately $9.06 million of gross revenue for the minimum scheduled period of the time charter

08:41 EST AcelRx publishes data in patients using SST for pain management - AcelRx Pharmaceuticals announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet, or SST, for pain management. The article entitled "Awake Plastic Surgery Procedures: The Use of a Sufentanil Sublingual Tablet to Improve Patient Experience" was authored by Hisham Seify from Newport Plastic Surgery in Newport Beach, California and published in Aesthetic Surgery Journal Open Forum with an accompanying video as supplemental material. The study was a prospective single cohort study conducted at his center. A total of 31 patients were enrolled. The most common procedures were liposuction, 71%, facelift, 10%, and blepharoplasty, 6%. Key findings from the study included: all 31 patients completed the plastic surgery procedures successfully without disruption from inadequate analgesia; no additional analgesics were provided intraoperatively or in the PACU, or post anesthesia care unit, for pain; the average recovery time was 15 +/- 4 minutes; patient vital signs were stable during the procedures and in recovery, and there was no oxygen desaturation observed and no supplemental oxygen required; three patients experienced nausea, only one of which required treatment with oral ondansetron 4 mg in the PACU, and one patient experienced dizziness.Study limitations include that there was a small sample size evaluated, and there was no control group of patients. Data collection is ongoing to examine outcomes in a larger number of patients.

08:39 EST Sellas Life announces completion of enrollment of Phase 1/2 trial of GPS - SELLAS Life Sciences (SLS) announced the completion of enrollment in the Phase 1/2 clinical trial of the Company's lead asset, galinpepimut-S, GPS, in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in second or third line Wilms Tumor-1 relapsed or refractory metastatic ovarian cancer. The endpoints of the study include safety, overall response rate, progression-free survival, overall survival and immune response correlates. The clinical trial is being conducted under a Clinical Trial Collaboration and Supply Agreement with Merck & Co (MRK). The total expected enrolled and evaluable number of patients is 17. Data from 15 patients will be examined by mid-2022, with final data analysis for all evaluable patients expected by the end of 2022. "Completion of enrollment is an important milestone as we work diligently to evaluate a much-needed therapeutic treatment option for second or third line relapsed or refractory metastatic ovarian cancer patients," said Angelos Stergiou, MD, ScD. h.c., President and Chief Executive Officer of SELLAS. "Our ability to complete enrollment timely, especially given the challenges related to COVID, is a tremendous accomplishment. We greatly appreciate the level of commitment Merck has given to this collaboration and are deeply grateful to all patients and their families, as well as investigators and study staff involved."

08:39 EST Stran & Company closes GAP Promo acquisition - Stran & Company announced the completion of its previously announced acquisition of GAP Promotions in an asset purchase transaction. Headquartered in Gloucester, Massachusetts, GAP Promo is a full-service promotions agency that designs, sources, and develops custom brand solutions for many of the world's leading beverage and consumer packaged goods companies. GAP Promo achieved sales of $7.4M in 2020 and has been profitable since inception in 2006. GAP Promo's expertise in point of sale, display, racks and more bolsters Stran's business in the beverage and consumer packaged goods sectors. Stran's product sourcing and development, technology, logistics and fulfillment expertise provides GAP Promo's customers with a broader array of new services and capabilities. The combined knowledge and capabilities are expected to generate growth opportunities across both organizations' existing clients, as well as help attract new clients. Gayle Piraino, founder and President of GAP Promo, will continue with the Company to lead the new GAP Promo business. Stran will also retain all of GAP Promo's current employees.

08:38 EST BAE Systems and FMV confirm bid submission for 'combat proven' CV90 - BAE Systems has confirmed its bid submission, together with the Swedish Defence Materiel Administration, FMV, for the advanced, combat-proven CV90 in response to the Ministry of Defence of the Slovak Republic's acquisition of 152 new Infantry Fighting Vehicles, IFV, in multiple variants. The offer will ensure the production and delivery of the CV90 in collaboration with local Slovak industry, on time and to budget. The joint filing by FMV and BAE Systems confirms the Swedish states' support for Slovakia, further strengthening governmental relations as the country looks to modernize its ground forces by 2030. The bid includes support with training, tactics, and future development and welcomes Slovakia as a member of the CV90 User Club.

08:36 EST eMagin announces demonstration of dPd technology on WUXGA display - eMagin Corporation announced the first public demonstration of the Company's flagship Direct Patterning Display technology on a widescreen ultra-extended graphics array OLED microdisplay that reached over 10,000 candela per square meter of maximum luminance in full color, which was showcased in customer monocular and binocular augmented reality headsets at the 2021 Interservice/Industry Training, Simulation and Education Conference in December.

08:35 EST Veru enters into clinical trial collaboration, supply agreement with Eli Lilly - Veru (VERU) announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly (LLY) and Company. The objective of the collaboration is to evaluate the efficacy and safety of enobosarm, Veru's new chemical entity, in combination with Lilly's Verzenio, a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer. "Independently conducted proof of concept preclinical studies in human breast cancer models have demonstrated that the combination of enobosarm with a CDK4/6 inhibitor had greater antitumor synergistic activity in tumor samples from patients who had breast cancer progression following treatment with palbociclib, a CDK4/6 inhibitor, and an estrogen blocking agent. The ENABLAR-2 trial will evaluate the efficacy and safety of the enobosarm and abemaciclib combination in patients that have previously received first line therapy of palbociclib and estrogen blocking agent combination in AR+ER+HER2- metastatic breast cancer," said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. "We are excited about potentially being an oral 2nd line therapeutic option in combination with abemaciclib for patients who have AR+ER+HER2- metastatic breast cancer. We are looking forward to our collaboration with Lilly on the ENABLAR-2 clinical trial." Under the terms of the non-exclusive clinical trial collaboration and supply agreement, Veru is responsible for conducting the clinical trial while Lilly will supply Verzenio for the study. Veru maintains full exclusive, global rights to enobosarm.

08:33 EST Point provides update on manufacturing, supply chain, late-stage programs - POINT Biopharma Global announced business progress updates, including the completion of its Indianapolis, Indiana production facility, as well as the scheduled presentation of dosimetry data from the lead-in cohort of the Company's Phase 3 trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting, taking place February 25-27, 2022. Manufacturing: POINT's Indianapolis manufacturing facility opened in October 2021, the Investigational New Drug amendment to add the facility to the Company's supply chain for the SPLASH trial occurred in December 2021, and production of no-carrier-added lutetium-177 PNT2002 clinical trial product commenced in January 2022. PNT2002: Dosimetry data from the SPLASH trial will be presented at SNMMI; the randomization phase is currently enrolling approximately 400 patients in both US and Canada. There are 21 sites currently enrolling in North America. Site activations throughout Europe and the UK are ongoing, and all sites are expected to be open by 2Q2022. The Company continues to expect to report top line data from SPLASH mid-2023. PNT2003: POINT is currently assessing the regulatory pathways for PNT2003 based on feedback and ongoing discussions with regulatory authorities. The Company is evaluating the following pathways: An ANDA for GEP NETs and an NDA for non-GEP NETs. Medical isotope supply: Will receive actinium-225 in 2022 from the US Department of Energy Isotope Program1 to support early-stage pipeline; in-house manufacturing of n.c.a. Lu-177 remains on track for launch in 2023. POINT will use Ac-225 to help drive ongoing studies to support transition of its early-stage pipeline to the clinic in 2023. DOE supply will supplement the anticipated supplies of Ac-225 from TerraPower, NorthStar Medical, and Ionetix - all expected in the medium term.

08:32 EST U.S. Cellular successfully bids for spectrum licenses in FCC Auction 110 - United States Cellular successfully executed its strategy to accumulate mid-band spectrum to enable its 5G growth strategy. Combining mid-band purchases of CBRS spectrum in Auction 105 and C-Band in Auction 107 with the spectrum acquired in recently-completed Auction 110, U.S. Cellular will have mid-band spectrum in the great majority of its operating footprint and over 80% of subscribers will be covered with mid-band spectrum depths of 100 MHz or more. U.S.Cellular successfully bid for spectrum licenses in the recent Federal Communications Commission Auction 110 and purchased 380 licenses covering 97% of its subscribers for an estimated total cost of $580M. The total cost, including gross bids as well as estimated relocation costs, results in an average price of $0.48 / MHz-pop versus the auction overall at $0.72 / MHz-pop.

08:26 EST RumbleON appoints senior finance executive, Narinder Sahai, as CFO - RumbleOn announced that Narinder Sahai has been appointed as the company's Chief Financial Officer. Mr. Sahai will serve as a member of the executive leadership team and report directly to RumbleOn's Chief Executive Officer, Marshall Chesrown, beginning February 1. Mr. Sahai is an accomplished finance and strategy executive bringing leadership experience from innovative hyper-growth and multi-billion-dollar companies. He has an impressive track record of success building and leading the finance teams at some of the largest organizations in the US. In his role as CFO at RumbleOn, Mr. Sahai will be responsible for leading RumbleOn's financial strategy, accounting, tax, treasury, planning & analysis, investor relations, and finance operations.

08:22 EST Full House announces proposed offering of additional senior secured notes - Full House Resorts announced that it intends, subject to market and other conditions, to offer an additional $100.0 million in aggregate principal amount of its senior secured notes due 2028 in a private debt offering that is exempt from the registration requirements of the Securities Act of 1933, as amended. The Additional Notes will be issued pursuant to the Indenture pursuant to which Full House issued $310.0 million of identical senior secured notes in February 2021. The Additional Notes will be, and the Original Notes are, senior secured obligations of the Company and will be guaranteed, jointly and severally, by all of its current subsidiaries and future restricted subsidiaries. Holders of a majority of the Original Notes have consented to the issuance of the Additional Notes and an increase in the available borrowings under its credit agreement from $15.0 million to $40.0 million. The Company intends to use the net proceeds from the Additional Notes offering: to develop, equip and open The Temporary by American Place, our planned temporary casino in Waukegan, Illinois which we intend to operate while we design and construct our permanent American Place facility, to pay the transaction fees and expenses of the offer and sale of the Additional Notes and for general corporate purposes.

08:19 EST Aldeyra announces results of Phase 2 trial of reproxalap - Aldeyra Therapeutics announced that results from the randomized, double-masked, vehicle-controlled, crossover Phase 2 clinical trial of reproxalap in an allergen chamber model have been published in the peer-reviewed journal Clinical Ophthalmology.1 Reproxalap, an investigational new drug, is a first-in-class reactive aldehyde species modulator that has been shown to mitigate inflammation in patients with allergic conjunctivitis and other eye diseases. "Although allergic conjunctivitis affects more than 20% of the U.S. population2 and up to 60% of patients require medication other than topical antihistamines,3 a new mechanistic pharmacologic treatment approach has not been available for decades," stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra. "This Phase 2 allergen chamber trial suggests that treatment with reproxalap could lead to rapid and durable improvement in the symptoms and signs of allergic conjunctivitis."

08:19 EST Arcutis Biotherapeutics completes enrollment of STRATUM Phase 3 trial - Arcutis Biotherapeutics announced the enrollment of the last subject in its STRATUM phase 3 pivotal trial for topical roflumilast foam in patients with seborrheic dermatitis. If positive, the Company expects the study to be sufficient basis to submit a New Drug Application, NDA, in the United States in first half of 2023. "Individuals with seborrheic dermatitis have lacked new topical treatment options for decades, and current therapies leave much to be desired. The rapid enrollment of our Phase 3 trial highlights the need for topical treatments for seborrheic dermatitis that are suitable for all areas of the body, including the scalp and face," said Patrick Burnett, MD, PhD, FAAD. "We are pleased to have completed enrollment in our pivotal Phase 3 study for roflumilast foam, marking another major milestone for our topical roflumilast clinical program. The STRATUM study was designed to generate robust safety, tolerability and efficacy data to support a potential regulatory filing."

08:18 EST Reservoir Media announces publishing deal with Oak Felder - Reservoir Media announced a worldwide publishing deal with #1 hit writer-producer Warren "Oak" Felder. The deal includes all of Felder's future works and expands on a joint venture established with Felder in 2017, through which Reservoir signed his accomplished songwriting and producing collective The Orphanage, initially comprised of Trevor Brown and Zaire Koalo, and later including Keith "Ten4" Sorrells.

08:17 EST ManTech wins five-year $118M contract to support NSWC - ManTech announced a five-year, $118M contract to support Naval Surface Warfare Center, NSWC, Crane with innovative technology solutions that will advance Intelligence, Surveillance and Reconnaissance for a range of unmanned aircraft systems including the MQ-4C Triton. ManTech was awarded this contract under the Department of Defense Information Analysis Center's multiple-award contract vehicle. "At ManTech, Intelligent Systems Engineering is a core competency where we excel at developing innovative solutions that set the bar for advancing the customer mission in new, exciting and unprecedented ways," said David Hathaway, Executive Vice President and General Manager of ManTech's Defense Sector. "Under this important recompete win, our aim is to ensure battle-space dominance at speed across the full range of combat scenarios."

08:14 EST Sarepta, GenEdit share progress on research collaboration - Sarepta Therapeutics and GenEdit announced a research collaboration and option agreement under which the companies are employing GenEdit's NanoGalaxy platform and Sarepta's gene editing technology to develop gene editing therapeutics for the treatment of neuromuscular diseases. As part of the agreement, Sarepta obtains exclusive option rights to license polymer nanoparticles developed by GenEdit in the collaboration for up to four neuromuscular indications selected by Sarepta. Initial in vivo results from the research collaboration between GenEdit and Sarepta have demonstrated the potential of GenEdit's polymer nanoparticles to deliver therapeutic cargo to specific muscle tissue after systemic administration to allow for targeted, non-viral systemic delivery of genetic medicines. "We've been impressed with the diversity of GenEdit's NanoGalaxy platform and its screening and selection process, which has generated a number of distinct polymers that deliver to muscle," said Doug Ingram, president and chief executive officer, Sarepta Therapeutics. "Sarepta is committed to the development of therapies for rare neuromuscular diseases, and we look forward to continuing to work with the team at GenEdit to advance effective gene editing-based treatments for these patients." In addition to research payments, under the terms of the collaboration and option agreement, GenEdit may receive up to $57M in near-term payments and is also eligible for significant future development, regulatory and commercial milestones and tiered royalties ranging from upper-single to low-double digits on future product sales. Additional financial details were not disclosed.

08:12 EST Kratos Defense, Kymeta announce strategic partnership - Kratos Defense & Security Solutions announced a strategic partnership to jointly develop products and solutions that will enable modern, virtualized ground systems to better leverage the capabilities of next generation mobile satellite antennas. Among the broader goals of the partnership are to advance the ability of ground systems to support, leverage, manage, and control electronically-steered and multi-purpose antennas to better support the capabilities of software-defined and multi-beam satellites. This effort will initially focus on joint development of a software-defined remote terminal that will support a variety of dynamic satellite connectivity applications. The Digitally-Transformed Remote Terminal will combine a Kymeta ESA with a software-defined uCPE based on Kratos OpenSpace technology, all in a unified terminal package. The OpenSpace Platform is the first and only commercially available software-defined and orchestrated ground system that allows satellite and communications operators to advance the digital transformation of their satellite networks. In order to deliver a solution that dynamically adapts to changes at the space layer while also supporting multiple functions at the network's edge, the jointly developed products will conform to industry standards, including the IEEE-ISTO Std 4900-2021: Digital IF Interoperability Standard, v1.0 from the Digital IF Interoperability Consortium.

08:12 EST High Tide missed deadline to file annual financial statements - High Tide announces that it has missed the deadline of January 31 to file the Company's audited annual financial statements and management discussion & analysis for the financial years ended October 31, 2021 and 2020, and the CEO and CFO certificates, all as required by National Instrument 51-102 and National Instrument 52-109. The delay is due, in part, to personnel challenges relating to the COVID-19 pandemic. Accordingly, the Company will inform the Alberta Securities Commission, or ASC, of its anticipated delay in filing the Documents and may apply to the ASC pursuant to Part 4 of National Policy 12-203 - Management Cease Trade Orders for a Management Cease Trade Order, or MCTO, pending the filing of the Documents, which MCTO will prohibit the Company's management from trading in the securities of the Company until such time as the Documents are filed. No decision has yet been made by the ASC on this application. The Company has been working with its auditors to finalize its reconciliation of the effective tax rate and income tax provisions for the year ended October 31, 2021, but to date have been unable to reconcile the deferred tax balance.

08:11 EST Singing Machine says subscriptions for digital music library increased 25% - The Singing Machine Company provided an update on the holiday results of operations for its rapidly expanding recurring subscription-based digital karaoke music services. Summary results were as follows: Subscriptions for the Company's digital music library service increased 25% as compared to the same period in December 2020. Integrated subscriptions through the Company's Premium WiFi Karaoke System realized a 371% increase in subscription revenue compared to the same period thru December 2020. This represents a significantly higher subscription adoption rate faster than unit sales growth. The Company delivered 20% unit sales growth for its Premium WiFi Karaoke System during an expanded pilot marketing program primarily offered through Costco and Sam's Club during the holiday shopping season in 2021. In Q3 2021, the Company announced the transformation of its majority shareholders through a $10 million capital markets transaction. As part of this transaction, Stingray Group became one of the Company's largest shareholder and a key strategic technology partner. Stingray is a critical partner for the delivery of the Company's digital music library, which is central to the emerging subscription based recurring revenue model. This is projected as a scalable, high EBITDA-margin offering and is expected to significantly contribute to the Company's overall EBITDA and profitability growth rates for the foreseeable future.

08:09 EST Calavo Growers names Steven Hollister as chairman of board of directors - The Board of Directors of Calavo Growers named Steven Hollister as Chairman of the Board of Directors effective immediately. Hollister served as Calavo's Interim Chief Executive Officer from Sept. 8 to Jan. 31. As previously announced, Brian Kocher assumes the role of Calavo's President and Chief Executive Officer today. J. Link Leavens, who had served as chairman since March 2020, will remain on the board.

08:08 EST Titan International signs exclusivity agreement with Kubota - Titan International and Kubota Tractor Corporation, or KTC, / Kubota Canada Limited, or KCL, have entered into an exclusivity agreement on select sizes of Titan's new Trac Loader II tires for compact and utility tractor models used in residential, commercial, agricultural, and light construction applications. This innovative tire, branded with Titan and Kubota both displayed on the sidewall of the tire, will bring new value to Titan and Kubota customers. Before entering into agreement with Titan, Kubota conducted testing on the new Trac Loader II.

08:08 EST Honeywell says Walmart to use Solstice N40 to reduce carbon footprint - Honeywell (HON) announced that Walmart (WMT) will use its reduced global-warming-potential refrigerant Solstice N40 in some stores in Mexico and Central America. The project will cover more than 160 new supermarket refrigeration systems in the region. The use of Solstice will help Walmart reduce its carbon footprint and improve energy efficiency. This project represents a potential reduction of 130,000 metric tons of CO2e.

08:06 EST NHTSA confirms Tesla vehicle recalls, as vehicles may fail to stop at stop signs - Tesla, Inc. is recalling 53,822 2016-2022 Model S and Model X, 2017-2022 Model 3, and 2020-2022 Model Y vehicles, the NHTSA confirmed. The "rolling stop" functionality available as part of the Full Self-Driving (Beta) software may allow the vehicle to travel through an all-way stop intersection without first coming to a stop, Tesla said. Tesla will perform an over-the-air software update that disables the "rolling stop" functionality, free of charge. Reference Link

08:06 EST Worksport to purchase manufacturing facility in New York - Worksport is set to expand its manufacturing operations by 222,000 square feet into the United States of America. The Company is under contract and conducting due diligence for a period of 70 days. This purchase would establish a strategic presence with a state-of-the-art facility in the Buffalo, NY suburb of Seneca, near ports, distribution hubs, and the Canadian border. As the Company's manufacturing systems began occupying more space than expected and demand across all product lines increased, management proactively pursued additional manufacturing capacity that its recently leased Canadian manufacturing facility could not support alone. With an effective 222,000 square feet sitting on over 15 acres of land, the facility spans approximately 150,00 square feet and comes equipped with a 17,229-square foot Automated Storage & Retrieval System standing 90 feet tall. This AS/RS can reduce labor costs and increase throughput by automatically loading, handling, storing, and picking 5,200 pallets weighing up to 3,000 lbs/pallet; a system representing 70,000 square feet of additional, fully automated warehouse space to support inventory demands and long-term growth. There are also five more acres of additional land where the Company can develop between 50,000 to 100,000 square feet of additional space over coming years. And the facility's footprint infrastructure already meets the Company's current power and height requirements, which will allow for quick and streamlined occupancy and setup. This manufacturing expansion would also align directly with the Company's direct to consumer push that management expects will result in strong profit margins and immediate market penetration, as the Company focuses on aggressive EBITA targets within the next 12-24 months. Worksport will update its shareholders on the purchase contract ratification, contingent upon no critical findings from Company due diligence, as well as the facility's full scale production readiness as they become material; management estimates to close no later than April 2022.

08:04 EST EDAP TMS CEO says entering 2022 'with high expectations' - EDAP TMS issued the following letter to shareholders: "As we closed the book on 2021, I am once again pleased by the success of the entire EDAP team in navigating through the ongoing pandemic that has made virtually all business operations far more challenging. Hitting on a few key highlights, we continued to see strong growth in our US HIFU treatment volumes, which, through December 31, increased 65% over the comparable twelve-month period in 2020. We believe robust year-over-year procedural growth is one of the most important leading indicators, as it directly reflects the increased adoption and utilization of Focal One by urologists even as the pandemic continued to weigh on hospital capital spending and activity for much of the year. The strategic investments that we are making in our U.S. marketing efforts are clearly driving much of the success we experienced in the fourth quarter of 2021. The addition of our U.S. CEO, Ryan Rhodes, along with the expansion of our U.S. infrastructure, has led to several very noteworthy Focal One placements during the quarter, including UC San Diego, Brigham and Women's Hospital in Boston, Cedars-Sinai Health System in LA, Henry Ford Health System in Detroit, Duke University in North Carolina and Prisma Health in South Carolina. In our view, the relationships we are building with these renowned and highly regarded medical institutions reflect the growing acceptance among physicians that Focal One represents as an important new, cutting-edge technology that more hospitals are likely to adopt over time. We believe these successful recent U.S. placements indicate positive adoption trends for our underlying technology, and we will continue to execute our marketing plan while making the appropriate level of investment to maximize our U.S. growth strategy. In addition to these successes, we also made meaningful progress advancing our earlier stage research and development activities, as we believe HIFU technology has broad clinical utility in other difficult to treat pathologies. Our Phase 2 study evaluating safety and efficacy of our Robotic Focal One in treating deep rectal endometriosis continues to progress. We expect to finalize patient recruitment in 2022, and diligently work through the six-month follow up period. We look forward to seeing the final results from this study. More recently, we were pleased to announce the publication of compelling pre-clinical results in the journal Cancers which highlighted the possibility of treating locally advanced pancreatic cancers with HIFU. Pancreatic adenocarcinoma is among the most aggressive of all cancers, with an overall five-year survival rate for patients of less than 5%. If ultimately successful, this would be a major breakthrough for these patients who are in desperate need of effective treatment options. Following our strong fourth quarter momentum and with a solid cash position, EDAP enters 2022 with high expectations. I am excited and optimistic about the many opportunities in front of us, and I am confident that we will deliver another successful year. I would like to thank the entire EDAP team for their tireless work and dedication to get us to this point and you, our shareholders, for your continued support."

08:03 EST Imperial Oil increases quarterly dividend 26% to 34c per share

08:02 EST electroCore completes enrollment in TRANSIT study of nVNS - electroCore announced enrollment has been completed for the TRANSIT study of non-invasive vagal nerve stimulation to reduce ileus after colorectal surgery. This randomized, participant blinded, sham-controlled study is being sponsored by the United Kingdom's National Institute for Health Research. The 97-patient study is led by Dr. Stephen Chapman, Clinical Research Fellow in the University of Leeds School of Medicine. The study is conducted at St. James Hospital in Leeds, England and Bradford Royal Infirmary in Bradford, England. Ileus occurs in 10-20% of patients who have undergone elective colorectal surgery. Ileus is a distressing condition characterized by abdominal distension, persistent vomiting, and delayed return of bowel function after surgery. For patients, it prolongs the length of hospital stays and increases the risk of serious complications such as pneumonia and venous thromboembolic events. For healthcare systems, ileus increases per-patient costs by up to 71%, particularly those associated with nursing care, laboratory investigations, and medications. Clinical endpoints in the TRANSIT study include the number of postoperative days to first flatus, first stool, first oral intake, hospital discharge, and the GI-2 composite outcome, a common clinical measure of return of bowel function. The amount of daily oral morphine equivalent requirements, as well as a number of safety and feasibility outcomes to inform potential future clinical research and use, will also be assessed. Study results are expected later this year and will be presented at an appropriate medical congress.

07:57 EST Manulife Financial receives approval from TSX for its NCIB - Manulife Financial announced that it has received approval from the Toronto Stock Exchange, or TSX, for its previously announced normal course issuer bid, or NCIB, permitting the purchase for cancellation of up to 97 million of its common shares, representing approximately 5% of Manulife's issued and outstanding common shares. As at January 31 Manulife had 1,942,706,408 common shares issued and outstanding. Having an NCIB in place will provide Manulife with the flexibility to purchase common shares as part of its capital management strategy which is designed to maintain healthy regulatory capital ratios while balancing the objective of generating shareholder value. In addition, Manulife intends to repurchase shares in order to mitigate the impact of a recently completed reinsurance transaction on diluted EPS and core EPS.

07:46 EST VIQ Solutions enters strategic partnership with LegalCraft - VIQ Solutions announced a strategic partnership with LegalCraft to create an integrated solution, using the Lexel platform, to optimize legal case analysis, trial preparation and real-time transcription to assist legal professionals globally.

07:38 EST Aleafia Health provides furhter update on convertible debt - Aleafia Health is providing a corporate update regarding its outstanding listed unsecured convertible debentures, issued on June 27, 2019 and maturing on June 27, 2022. Further to the Company's announcement on January 4, 2022, Aleafia Health is advancing towards achieving a beneficial outcome for all its stakeholders. The Company has entered into a Forbearance Agreement with Debenture holders representing 58% of the Debentures' aggregate principal amount outstanding. An ad hoc Steering Committee comprised of certain Debentureholders, and represented by Bennett Jones, has been established that will help facilitate ongoing negotiations surrounding the Convertible Debt. The Forbearance Agreement's initial term extends to February 28, 2022, and the agreement automatically renews for 14-day periods thereafter unless notice to the contrary is provided. Under the Forbearance Agreement, the Holders, among other considerations, forebear in enforcing their rights or remedies against the Company under the Indenture and otherwise at law with respect to the non-payment of interest until the expiry of the Term. The Company, in turn, has agreed to certain customary and standard covenants regarding carrying on business in the ordinary course during the Term. Under the Forbearance Agreement, the Holders and the Company have agreed to work expeditiously and in good faith to negotiate a potential transaction to amend the terms associated with the Convertible Debt. There can be no assurance that the negotiations will result in a transaction.

07:37 EST Biogen exercises option to participate in developing Genentech's mosunetuzumab - Biogen announced that it exercised its option to participate in the development and commercialization of mosunetuzumab. Biogen will pay a $30M one-time option fee to Genentech, a member of the Roche Group, as part of the companies' long-standing collaboration on antibodies targeting CD20. Biogen will have joint decision-making rights related to development and commercialization of mosunetuzumab and Genentech will continue to lead the strategy and implementation of the program. Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody in development for the treatment of people with B-cell non-Hodgkin's lymphoma. Genentech plans to complete a Biologics License Application submission to the FDA in the near future for approval consideration from the GO29781 study investigating mosunetuzumab in patients with R/R FL. Roche recently submitted the initial marketing authorization application for mosunetuzumab to the European Medicines Agency. In addition, mosunetuzumab recently began a Phase 1b trial in patients with systemic lupus erythematosus.

07:36 EST Trevi Therapeutics completes enrollment in Phase 2b/3 PRISM study - Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis and expects to report top-line data in the second quarter.

07:35 EST Civitas Solutions acquires Bison Oil & Gas II for approximately $346M - Civitas Resources announced that it has signed definitive agreements to acquire privately held Denver-Julesburg Basin operator Bison Oil & Gas for approximately $346M of consideration, consisting of 2.3M CIVI shares, $45M in cash and the assumption of approximately $176M in debt and other liabilities . The Transaction is expected to close in the first quarter of 2022 and demonstrates Civitas' disciplined approach to consolidation with a focus on value creation and accretion. Kimmeridge Energy, Civitas' second largest shareholder, commented: "In just a short period of time, Civitas has established itself as a leading platform in the DJ Basin, with scale, resources and a demonstrated commitment to delivering unprecedented value to all of its stakeholders. We are very pleased with the integration progress of Civitas' legacy companies and firmly believe that the Company is well positioned to continue successfully executing its business plan, with a clear objective of identifying value-accretive opportunities."

07:34 EST Cytokinetics announces topline results from Cohort 3 of REDWOOD-HCM study - Cytokinetics announced positive topline results from Cohort 3 of REDWOOD-HCM, the Phase 2 clinical trial of aficamten, an investigational next-generation cardiac myosin inhibitor in development for the potential treatment of hypertrophic cardiomyopathy. HCM. Cohort 3 of REDWOOD-HCM enrolled patients with symptomatic obstructive HCM and a resting or post-Valsalva left ventricular outflow tract gradient of greater than or equal to 50 mmHg. All patients received up to three escalating doses of aficamten once daily. Overall treatment duration was 10 weeks with a 4-week follow up period after the last dose. In total, thirteen patients were enrolled and all patients completed the study on treatment. Results from Cohort 3 showed that substantial reductions in the average resting LVOT-G as well as the post-Valsalva LVOT-G were achieved. These clinically relevant decreases in pressure gradients were achieved with only modest decreases in average left ventricular ejection fraction; there were no patients whose LVEF fell below the prespecified safety threshold of 50%. Pharmacokinetic data were similar to those observed in Cohorts 1 and 2. In addition, the safety and tolerability of aficamten were consistent with prior experience in REDWOOD-HCM. "We are encouraged by the clinically relevant reductions in the LVOT gradient observed in these medically refractory patients and are pleased with the safety profile of aficamten when administered in combination with disopyramide," said Fady Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. "These results represent the first report of patients with obstructive HCM treated with a combination of a cardiac myosin inhibitor and disopyramide and support our plan to include this patient population in SEQUOIA-HCM, our Phase 3 trial, which is important given these patients have exhausted other available medical therapies. We look forward to initiating screening of patients in SEQUOIA-HCM soon and look forward to sharing these results from Cohort 3 with the medical community in April."

07:31 EST Windtree Therapeutics completes enrollment in Phase 2 study of lucinactant - Windtree Therapeutics announced it has completed enrollment in its Phase 2 study of lucinactant for patients with COVID-19 associated lung injury and acute respiratory distress syndrome, ARDS. Data is anticipated in the first quarter of 2022. The Phase 2 trial is a multicenter, single-treatment study in 20 patients designed to evaluate the safety and tolerability of lucinactant delivered as a liquid via the endotracheal tube in patients who are mechanically ventilated as a result of COVID-19 associated acute lung injury. "COVID-19 infection can cause serious lung injury resulting in acute respiratory distress syndrome where surfactant destruction and abnormalities may be a contributing factor. This initial pilot study is to determine if we can safely administer lucinactant as a surfactant replacement in these severely ill patients and to learn about potential dosing and respiratory benefits," said Steve Simonson, MD, Chief Medical Officer of Windtree Therapeutics. "We are pleased to have completed enrollment and look forward to data from this trial in this first quarter of 2022."

07:28 EST Verano Holdings to acquire Goodness Growth in $413M all-share transaction - Verano Holdings Corp. (VRNOF) and Goodness Growth Holdings, Inc. (GDNSF) are pleased to announce that they have entered into a definitive arrangement agreement pursuant to which Verano will acquire all of the issued and outstanding shares of Goodness in an all-share transaction valued at approximately $413M on a fully-diluted basis. Under the terms of the Arrangement Agreement, it is expected that each holder of Goodness subordinate voting shares will receive 0.22652 of a Verano Class A subordinate voting share for each Goodness subordinate voting share held and each holder of Goodness multiple voting shares and Goodness super voting shares will receive 22.652 Verano Shares for each Goodness multiple voting share and Goodness super voting share held, respectively. Goodness' active operations include 18 dispensaries; five cultivation and processing facilities; a research and development facility; and the Vireo, 1937, LiteBud, Kings & Queens, Hi-Color, and Amplifi product brands. The acquisition of Goodness is expected to expand Verano's operational footprint with the addition of the New York, Minnesota and New Mexico markets, strategically increasing the Company's presence in the Northeast, Midwest and Southwest, while adding a suite of established cannabis brands to the Company's portfolio. The Transaction will be effected by way of a plan of arrangement pursuant to the Business Corporations Act. Under the terms of the Arrangement Agreement, Verano will acquire all of the issued and outstanding Goodness Shares, with each holder of Goodness subordinate voting shares expected to receive 0.22652 of a Verano Share for each Goodness subordinate voting share held, and each holder of Goodness multiple voting shares and Goodness super voting shares expected to receive 22.652 Verano Shares for each Goodness multiple voting share and each Goodness super voting share held, respectively, implying a current market price per Goodness subordinate voting share of US$2.39, based on the closing share price of Verano and the Bank of Canada exchange rate on January 31, 2022. Based on the 15-Day volume weighted average price of Verano ending January 27, 2022 and a CAD/USD exchange rate of 0.790, the Transaction implies a price per Goodness subordinate voting share of US$2.64. After giving effect to the Transaction, Goodness shareholders are expected to hold in aggregate approximately 10.1% of the issued and outstanding pro forma Verano Shares. In accordance with the terms of Goodness' 2019 Company Equity Incentive Plan, the terms of each Goodness option and RSU will be adjusted to entitle the holder to receive, upon exercise, in substitution for the number of Goodness Shares subject to such option or RSU, that number of Verano Shares based on the Exchange Ratio. In accordance with the terms of Goodness' outstanding warrants, the terms of each Goodness warrant will be adjusted to entitle the holder to receive, upon exercise, in substitution for the number of Goodness Shares subject to such warrant, that number of Verano Shares based on the Exchange Ratio. Goodness shareholders holding approximately 36.7% of the voting power of the issued and outstanding Goodness Shares have agreed to vote in favor of the Transaction pursuant to voting and support agreements. In addition, the Chief Executive Officer of Goodness has entered into a lock-up agreement with the Company, pursuant to which such shareholder has agreed not to transfer any Verano Shares received in connection with the Transaction for a period of 12 months following the effective date of the Transaction. Pursuant to the terms of the Lock-Up Agreement, 20% of the covered securities will be released on the effective date of the Transaction with an additional 20% being released every three months. The Arrangement Agreement provides for customary provisions, including covenants in respect of non-solicitation of alternative transactions, $14.875M reciprocal termination fees under certain circumstances and reciprocal expense reimbursement provisions in certain circumstances. Implementation of the Transaction is subject to the approval of at least two-thirds of the votes cast by Goodness shareholders present in person or represented by proxy at the Meeting, voting as a single class, and pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"), the approval of the majority of the votes cast by the holders of Goodness subordinate voting shares, the Goodness multiple voting shares and the Goodness super voting shares, on a class basis, excluding the votes of Goodness shareholders whose votes are required to be excluded for the purposes of "minority approval" pursuant to MI 61-101. The Transaction is subject to the approvals of the Supreme Court of British Columbia, receipt of U.S. regulatory approvals, including pursuant to the Hart-Scott-Rodino Antitrust Improvements Act and New York State regulatory requirements, and other customary conditions of closing. The Transaction has been unanimously approved by the Boards of Directors of each of Verano and Goodness. The Board of Directors of Goodness has unanimously determined, after receiving financial and legal advice from outside advisors and a unanimous recommendation from a committee of independent directors, that the Transaction is in the best interests of Goodness, and that, on the basis of the Fairness Opinions, that the consideration to be received by the Goodness shareholders is fair, from a financial point of view. The Goodness Board unanimously recommends that Goodness shareholders vote in favour of the resolution to approve the Transaction that will be set forth in the Circular. The Board and the Transaction Committee obtained a fairness opinion from Hyperion Capital Inc., and the Transaction Committee obtained an independent fairness opinion from Cormark Securities Inc., which provide that, as at the date of such opinions and based upon and subject to the assumptions, procedures, factors, limitations and qualifications set forth therein, the consideration to be received by the Goodness shareholders pursuant to the Transaction is fair, from a financial point of view, to the Goodness shareholders.

07:27 EST Digihost mined 62.58 BTC in January - Digihost Technology provided unaudited Bitcoin production updates for the month ended January 31, 2022. All amounts are expressed in USD unless otherwise indicated. The Company mined approximately 62.58 BTC in January 2022, an increase of 28.88 BTC or 86% compared to January 2021. Using the January 31, 2022 and January 31, 2021 closing BTC prices, respectively, the value of the Company's BTC mined in January 2022 increased by approximately $1.3M, or approximately 116%, compared to January 2021. Production Highlights for January 2022: Mined 62.58 BTC increasing total holdings to 698.64 BTC valued at approximately $26.9 million as of January 31, 2022 based on a month end BTC price of $38,500; Total Ethereum holdings of 1,000.89 ETH valued at approximately $2.7 million as of January 31, 2021 based on a month end ETH price of $2,650; Total digital currency inventory value consisting of BTC and ETH of approximately $29.6 million as of January 31, 2022; The Company's current hashrate is approximately 415PH and is expected to increase to approximately 1.2EH by the end of Q1 2022.

07:22 EST Lantronix launches application-specific industrial IoT solutions - Lantronix announced its launch of application-specific industrial IoT solutions that address concerns in Industry 4.0, Security and Transport markets with its G520 Series Smart cellular IoT devices and services. Now available are the G520 Industrial, a competitive cellular industrial protocol converter router; and G520 Security, a high-speed LTE CAT13 and 5G communication router to reduce cybersecurity threats. G520 Transport will be launched later in 2022. The G520 industrial and security gateways offer a complete solution and comes pre-configured with Lantronix's ConsoleFlow cloud-based device management, which increases operational efficiency by providing a single pane from which to manage remote assets. It also comes pre-configured for Lantronix Connectivity Services, which provide North American and global cellular data plans and VPN security with an easy-to-use cloud platform to manage SIMs and services.

07:21 EST Anavex announces results from Phase 3 trial of ANAVEX 2-73 - Anavex Life Sciences reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX 2-73 in adult female patients with Rett syndrome and demonstrated a statistically significant improvement over placebo for the primary efficacy endpoint as well as for all the secondary efficacy endpoints. Convenient once daily oral liquid doses of up to 30mg ANAVEX(R)2-73 was well tolerated with very good medication compliance. Rett syndrome is a chronic CNS disease caused by a spontaneous mutation of one gene, MECP2. In the primary endpoint, RSBQ AUC, ANAVEX2-73 induced a statistically significant and clinical meaningful improvement in 72.2% of patients as compared to 38.5% on placebo. The secondary efficacy endpoints also demonstrated statistically significant and clinical meaningful improvements. For the ADAMS, a measure of emotional behavior symptoms, a significantly higher proportion of ANAVEX2-73 treated adult patients with Rett syndrome than placebo-treated patients showed improvement. For the CGI-I, more patients achieved clinically meaningful CGI-I response over the treatment duration in the ANAVEX2-73-treated group than in the placebo group. Based on the results in this Phase 3 study and the prior successful U.S. Phase 2 study in adult patients with Rett syndrome, Anavex is planning to meet with FDA to discuss the approval pathway. There are no FDA-approved drugs for Rett syndrome. ANAVEX2-73 has Fast Track designation, Rare Pediatric Disease designation and Orphan Drug designation from the FDA for the treatment of Rett syndrome and may be considered for accelerated approval. "This is now the second successful placebo-controlled study of ANAVEX2-73 in adult patients with Rett syndrome, and this Phase 3 study builds on the platform potential of ANAVEX2-73 and its ability to demonstrate clinically meaningful improvements in Rett syndrome symptoms in the ANAVEX2-73 treatment group compared to placebo," said Christopher Missling, PhD, President & Chief Executive Officer of Anavex. "I would like to thank the patients and caregivers who participated in this trial, the Anavex team, trial clinics, and doctors who have worked tirelessly on this program. Special thanks go to the supportive Rett Syndrome advocacy groups in the countries where our program has been implemented. We look forward to continuing the journey together."

07:18 EST Zegna sees FY21 adjusted EBIT margin of around 10% - Ermenegildo Zegna announced the Company's unaudited Fiscal Year 2021 Preliminary Revenues. Ermenegildo "Gildo" Zegna, Chairman and CEO of the Zegna Group, commented: "Our first financial release as a publicly listed company confirms that Zegna is a global leader in the luxury market. Our focus on excellence, innovation and the strong customer response to our luxury leisurewear, resulted in our preliminary full year revenues outpacing our previously disclosed Plan.1 By focusing on our legacy brand - which is going through a major rebranding - and on the further strengthening of our one-of-a-kind Made in Italy luxury textile platform coupled with the dynamic pace at which Thom Browne continues, we were able to deliver a strong financial performance in 2021. While we will continue to monitor world events and the COVID pandemic's potential impacts on our business, we remain optimistic about our growth in 2022, with improved profitability."

07:18 EST OneWater Marine's T-H Marine announces acquisition of JIF Marine - OneWater Marine announced that its subsidiary, T-H Marine, has acquired JIF Marine, a supplier of stainless steel ladders, dock products, and other accessories for recreational marine applications. "The OneWater family looks forward to welcoming Jimmy Freudenberg and the JIF Marine team as we continue to grow the higher margin marine parts and accessories business. T-H Marine made a great fit for us back in November, as their history of accretive acquisitions aligns well with OneWater's business model and growth strategy. We were very optimistic about the additional platform for growth with T-H Marine having its own acquisition pipeline, and we are seeing the benefits materialize with the first opportunity of many in JIF Marine," said Austin Singleton, Chief Executive Officer for OneWater.

07:16 EST Clene appoints Morgan Brown as Chief Financial Officer - Clene (CLNN) announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. In his prior roles, Brown has participated in and led efforts to evaluate, negotiate, and close transactions including equity and debt financings totaling over $1 billion and out-licensing of commercial stage asset transactions totaling $220 million. Since 2013, he has been Executive VP and CFO of Lipocine (LPCN).

07:14 EST Clene appoints Morgan Brown as Chief Financial Officer - Clene (CLNN) announced the appointment of Morgan Brown as Chief Financial Officer effective Feb. 1, 2022. In his prior roles, Brown has participated in and led efforts to evaluate, negotiate, and close transactions including equity and debt financings totaling over $1 billion and out-licensing of commercial stage asset transactions totaling $220 million. Since 2013, he has been Executive VP and CFO of Lipocine (LPCN).

07:14 EST Uber, Wallbox to expand partnership nationwide - Uber (UBER) and Wallbox (WBX) are expanding their partnership nationwide following the pilot program. As previously announced, the partnership provides Uber drivers a discounted package for a Wallbox Pulsar Plus charger, installation and the option to finance the package. Just a few months after beginning their initial partnership in the Bay Area in October 2021, the companies are expanding their collaboration so that drivers across the U.S. will soon have access to Wallbox's discounted EV charging package. This will be rolled out in four key groups, in order to reach nationwide coverage by the end of April. Additionally, the two companies are actively discussing a potential global roll-out program beginning in Europe and Canada. The roll-out is expected to follow four phases; the first covering Los Angeles, Portland and Seattle in January, the second covering Phoenix, New York and Boston in February, the third covering the Midwest and Southeast in March, and the final phase covering the rest of the U.S. excluding Alaska in April.

07:14 EST Aterian appoints Susan Lattmann, Sarah Liebel to board of directors= - Aterian (ATER) announced that Susan Lattmann and Sarah Liebel have joined the Company's Board of Directors. In addition, Greg Petersen plans to transition off the Board effective April 1, 2022, following the end of the first quarter and the reporting of the Company's 10-K for the 2021 fiscal year. Lattmann, who is an experienced executive and corporate board director, having spent more than 23 years at Bed Bath & Beyond (BBBY) in leadership roles, has joined the Compensation and Audit Committee and is expected to chair the Audit Committee following the departure of Greg Petersen. Liebel has joined the Compensation and Nominating and Corporate Governance Committee. Liebel currently serves as Chief Revenue Officer at 1stdibs.com (DIBS), where she oversees the sales and operations teams at the company, including Customer Experience, Logistics, Business Operations, Trade & Private Client sales.

07:12 EST Neximmune announces research collaboration with Rutgers University - NexImmune announced a collaboration with Rutgers, The State University of New Jersey. The collaboration will focus on the discovery and development of novel therapies targeting immune checkpoint proteins for the treatment of neuroendocrine tumors and other cancers. "Neuroendocrine tumors are being diagnosed with increasing frequency in the United States and represent a large unmet medical need," said Dr. Jerry Zeldis, NexImmune's Executive Vice President, R&D. "With Dr. Libutti, we hope to discover and develop novel treatments utilizing our AIM ACT platform that may improve the timely and effective treatment of neuroendocrine neoplasia."

07:11 EST Waters acquires charge detection mass spectrometry technology - Waters Corporation announced it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass Spectrometry CDMS technology and services. Financial details of the transaction are not being disclosed. Founded in 2018 by professors Martin Jarrold and David Clemmer at Indiana University, Megadalton Solutions has developed CDMS instrumentation that makes it possible to analyze extremely large proteins and protein complexes, such as those used in cell and gene therapies, that would otherwise be difficult to analyze with conventional mass spectrometry. Waters became a strategic investor in the company and in 2021 brought Megadalton's CDMS technology into the Waters Immerse Cambridge innovation and research lab for advanced testing and development. "Large molecule mass spectrometry with CDMS offers an important tool for the characterization, analysis and quantification of next-generation biologics, such as cell and gene therapies, which is an area of high interest among biopharmaceutical and biomedical research customers," said Dr. Udit Batra, President and CEO, Waters Corporation. "Large molecules can be extremely challenging to characterize with conventional mass spectrometry because of their complexity. We are looking forward to further developing and commercializing the Megadalton CDMS technology to help customers analyze and quantify large molecules in applications such as cell and gene therapy drug development."

07:11 EST CytoSorbents enrolls first patient in Procyss controlled trial - CytoSorbents announced that the first patient has been enrolled in the PROCYSS, a Prospective, Randomized, controlled trial with use Of CYtoSorb to reverse refractory Septic Shock, trial in Germany by Stefan Kluge, Director, Department of Intensive Care Medicine at the University Hospital Hamburg Eppendorf and lead investigator of the PROCYSS trial. CytoSorbents Enrolls First Patient in the PROCYSS Multicenter RCT Evaluating CytoSorb in Refractory Septic ShockRefractory septic shock, or RSS, is the persistent and potentially fatal drop in blood pressure despite fluid resuscitation and high dose vasopressor use, seen in patients with life-threatening infection and sepsis. Despite standard of care therapy, the majority of patients with RSS will die. Given that severe hyperinflammation is thought to contribute to RSS, broad spectrum removal of inflammatory mediators such as cytokines using CytoSorb blood purification, has demonstrated significant promise in real-world clinical usage and is now being formally evaluated in PROCYSS.

07:10 EST Resource Capital Fund to nominate three director candidates to IAMGold's board - Resource Capital Fund VII L.P., a fund managed by RCF Management L.L.C., owning approximately 5.2% of the issued and outstanding common shares of IAMGOLD, released an open letter to IAMGOLD's board of directors and announced that it will be nominating a slate of at least three highly qualified director candidates who will provide the deep mining, operational and governance experience the current Board desperately needs. RCF is pleased to announce that its slate of nominees will include Maryse Belanger, David S. Smith and Lawrence P. Haber. RCF reserves its right to nominate additional directors in accordance with applicable securities and corporate law. "Our nominees are independent and accomplished world-class directors who bring vast mining experience and knowledge," said Martin Valdes, Partner, Head of Resource Capital Fund VII L.P. "They also share a common and very achievable goal: to create a much-needed culture of operational excellence, integrity and accountability at IAMGOLD, which is essential if IAMGOLD is to reach its full potential."

07:08 EST KKR to invest in PlayOn Sports, terms undisclosed - PlayOn Sports and KKR announced the signing of a definitive agreement under which KKR will make an investment in PlayOn, alongside PlayOn's existing shareholder, Panoramic Ventures. The investment will support the company's growth as it continues to focus on building products and experiences for state associations, high schools, high school athletes and their fans across the country. Financial terms were not disclosed. KKR is making its investment in PlayOn through its North American private equity strategy. The transaction is expected to close in Q1, subject to customary closing conditions.

07:08 EST Telesat selects Cobham SATCOM for Telesat Lightspeed Landing Station terminals - Telesat and Cobham SATCOM have announced an Agreement to deploy high-performance Cobham SATCOM 3-axis TRACKER 4000 terminals for the Telesat Lightspeed Landing Station network. Under the terms of the agreement, Cobham SATCOM will manufacture, integrate, and install advanced Ka-band tracking antennas at Telesat's sites throughout the world, and provide long-term logistics and maintenance support. "The radome-protected antennas will provide accurate tracking in the most adverse weather conditions, ensuring high availability and throughput for carrier-grade performance," the company said. Cobham SATCOM will integrate the TRACKER antennas with baseband modems from SatixFy, to enable the Telesat Lightspeed network to provide 15 Tbps of global network capacity.

07:08 EST Scotts Miracle-Gro sees 2021 U.S. consumer segment sales (2%) - 2% - The Company said the better-than-expected result in U.S. Consumer, coupled with additional pricing actions that will take effect in the third quarter, is allowing it to increase full-year sales guidance in the segment to a range of plus 2 percent to minus 2 percent. This compares to a previous range of flat to minus 4 percent. The improved guidance does not require the Company to adjust its outlook for the balance of the lawn and garden season but allows it to maintain guidance for adjusted earnings per share despite its recently revised reduction in the full-year sales outlook for Hawthorne.

07:06 EST Microsoft, Striim collaborate for database modernization in Azure Cloud - Microsoft and Striim announced an expansion of their strategic relationship with a new assessment and migration managed service "providing fast, automated migration of enterprise databases from on-premises or a cloud to Microsoft Azure databases. This collaboration accelerates the data modernization journey to Azure, helping enterprises modernize their business applications and deploy new cloud-native applications, while maintaining business continuity," the company said. This service offering is the latest addition to Striim's relationship with Microsoft. The new Striim Database Migration Service, StreamShift, now supports enterprises moving from database sources such as Oracle, MySQL, PostgreSQL, MariaDB, and MongoDB to Microsoft Azure.

07:04 EST ObsEva appoints Katja Buhrer as Chief Strategy Officer - ObsEva announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company's Executive Committee, effective February 1, 2022. Buhrer will oversee a range of operational areas including corporate strategy, investor relations and public relations. Buhrer's was previously Vice President Corporate Development, Investor Relations, and Chief of Staff at Kindred Biosciences, a veterinary biopharmaceutical company.

07:02 EST Sirius XM board declares special cash dividend of 25c per share - SiriusXM announced that its Board of Directors declared a special cash dividend of 25c per share, payable on February 25, 2022, to stockholders of record as of the close of business on February 11, 2022. The total amount of the special cash dividend is expected to be approximately $1B. This special dividend is in addition to the regular quarterly cash dividend that SiriusXM's Board declared on January 26, 2022. SiriusXM increased its regular quarterly cash dividend by 50% in October 2021.

06:55 EST Brookfield Renewable announces electricity purchase agreement with Lievre - Hydro-Quebec and Evolugen, the Canadian operating business of Brookfield Renewable, announced that they have entered into a 40-year escalating electricity purchase agreement under which Hydro-Quebec will purchase the output of the Lievre hydro-electric portfolio in Quebec with 263 MW of capacity. The assets will continue to be operated by Evolugen. The facilities will contribute approximately 1.5 TWh annually, which is equivalent to the energy used by close to 90,000 homes. The agreement involves integrating Evolugen's Lievre generating fleet, into Hydro-Quebec's generation planning. It also includes priority access rights associated with the US market.

06:54 EST SunCoke Energy sees FY22 domestic coke production 4.1M tons - Sees FY22 adjusted EBITDA $240M-$255M. Sees FY22 capital expenditures $80M. Sees FY22 cash taxes $8M-$12M.

06:52 EST PJT Partners raises dividend 5c to 25c - The Board of Directors of PJT Partners has declared a quarterly dividend of 25c per share of Class A common stock, an increase from the previous ordinary dividend of 5c per share of Class A common stock. The 25c dividend will be paid on March 23 to Class A common stockholders of record on March 9.

06:43 EST Janus Henderson Group appoints Trian's Nelson Peltz, Ed Garden to board - Janus Henderson Group announced that it is expanding its Board of Directors with the addition of two new members. Nelson Peltz and Ed Garden of Trian Partners will join as Independent Non-Executive Directors, effective February 1. Peltz is CEO and a Founding Partner of Trian Partners, and Garden is Trian's Chief Investment Officer and a Founding Partner. Trian beneficially owns approximately 16.7% of Janus Henderson's outstanding common stock. With these appointments and the previously announced appointment of Alison Davis, the company has added three new independent directors since February 2021. The Board will now consist of 12 members, 11 of whom are independent.

06:41 EST AT&T to expand fiber footprint to cover 30M customer locations by YE 2025

06:40 EST AT&T sees net debt to adjusted EBITDA ratio of 2.5x by year-end 2023 - AT&T expects to use the estimated $43B in proceeds from the transaction to deleverage and position the company as one of the best capitalized 5G and fiber broadband companies in the United States, the company said in a statement. AT&T expects a Net Debt to Adjusted EBITDA ratio of 2.5x by year end 2023.

06:39 EST AT&T to spin off interest in WarnerMedia after closing of Discovery transaction - AT&T, Inc. (T) announced that its board of directors has determined to spin off AT&T's interest in WarnerMedia in connection with the previously announced transaction with Discovery, Inc (DISCA). The transaction, which will spin off 100% of AT&T's interest in WarnerMedia to AT&T's existing shareholders in a pro rata distribution, followed by the merger of WarnerMedia with Discovery, is expected to close in the second quarter of 2022. Additionally, AT&T's board of directors approved an expected post-close annual dividend of $1.11 per AT&T share, to account for the distribution of WarnerMedia to AT&T shareholders and to size the annual dividend payout at approximately 40% of projected free cash flow1 to enable investment in attractive growth opportunities. As previously disclosed, under the terms of the transaction, which is structured as an all-stock, Reverse Morris Trust transaction, AT&T will receive $43B in a combination of cash and other consideration, and AT&T's shareholders will receive stock representing approximately 71% of the new company, Warner Bros. Discovery, Inc., on a fully diluted basis. Existing Discovery shareholders will own approximately 29% of the new company on a fully diluted basis. "In evaluating the form of distribution, we were guided by one objective - executing the transaction in the most seamless manner possible to support long-term value generation," said AT&T CEO John Stankey. "We are confident the spin-off achieves that objective because it's simple, efficient and results in AT&T shareholders owning shares of both companies, each of which will have the ability to drive better returns in a manner consistent with their respective market opportunities. We believe that the remaining AT&T and the new WBD are two equities that the market will want to own and the markets to support those equities will develop," Stankey said. "Rather than try to account for market volatility in the near-term and decide where to apportion value in the process of doing an exchange of shares, the spin-off distribution will let the market do what markets do best. We are confident both equities will soon be valued on the solid fundamentals and attractive prospects they represent." Following the closing of the transaction, the WBD common stock is expected to be listed on the NASDAQ Global Select Market under the ticker "WBD."

06:38 EST AT&T board approves post-close annual dividend of $1.11 per share

06:37 EST AT&T to spin off interest in WarnerMedia after closing of Discovery transaction

06:36 EST MediciNova receives new patent in Korea for MN-001 - MediciNova announced that it has received a new patent from the Korean Intellectual Property Office which covers MN-001, or tipelukast, for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034. The allowed claims cover a pharmaceutical composition comprising MN-001 for reducing a triglyceride blood level, reducing a total cholesterol blood level, and reducing a low-density lipoprotein blood level.

06:35 EST Northern Oil and Gas raises cash dividend 75% to 14c per share - Northern Oil and Gas announced that its Board of Directors has declared a cash dividend on the company's common stock in the amount of 14c per share, representing a 75% increase from the prior quarterly dividend. The dividend is payable on April 29 to stockholders of record as of the close of business on March 30.

06:31 EST UBS financial targets include 15%-18% return on CET1 capital - Financial targets include 70%-73% cost/income ratio and 10%-15% GWM PBT growth.

06:30 EST UBS intends to repurchase up to $5B of shares during 2022

06:28 EST TransAlta invests $2M in Ekona Power - TransAlta announced that it has made a $2M equity investment in Ekona Power's Series A funding round. The investment will help support the commercialization of Ekona's novel methane pyrolysis technology platform, which produces cleaner and lower-cost turquoise hydrogen. The investment will provide TransAlta with a seat on Ekona's strategic committee, whose members will receive project updates, guide development and become priority commercialization partners if the technology is successful. TransAlta believes hydrogen, as a fuel source, is a promising pathway to decarbonize the electricity sector and provide dispatchable, net-zero generation.

06:24 EST Greenwich LifeSciences provides update on Phase III trial of Flamingo-01 - Greenwich LifeSciences provides an update on the Phase III clinical trial, FLAMINGO-01. The Company has made significant progress towards study initiation: Contract Research Organization has been contracted for study start-up, project management, data management, and clinical data monitoring; Manufacturing of third clinical lot of GP2 using a commercial line has been completed; Commercial lots of GP2 active ingredient for filing of BLA have been contracted; Central Laboratory has been contracted for screening of HLA type; Drug and biological sample storage sites and other study infrastructure have been put in place; Central Institutional Review Board (IRB) approval has been granted for the study; Clinical trial sites continue in the study start-up process and the Company continues to solicit additional US and international sites and networks for participation in the study.

06:23 EST M.D.C. Holdings sees Q1 home deliveries 2,000-2,300 - Sees Q1 average selling price $550,000-$560,000. Sees Q1 gross margin 25%.

06:15 EST Enterprise Products sees 2022 growth capital investments $1.5B - The company said, "For 2022, we expect growth capital investments to be approximately $1.5 billion. This estimate does not include capital investments associated with the partnership's proposed deepwater Seaport Oil Terminal, which remains subject to governmental approval. We currently expect sustaining capital expenditures for 2022 to be approximately $350 million."

06:12 EST Eneti provides updates on different contracts - Eneti announced that it has discontinued discussions with a shipyard in the U.S. to build a Jones Act-compliant Wind Turbine Installation Vessel. Emanuele A. Lauro, CEO said, "We believe the US Market for offshore wind will offer significant opportunities for the company in the future, but right now we are focused on delivering on our existing commitments and deriving value from our existing fleet." Furthermore, the Company announced that, Seajacks UK Limited, a wholly-owned subsidiary of the Company and a leading provider of installation and maintenance vessels to the offshore wind sector, has signed four contracts with customers in NW Europe for between 189 to 240 days of employment for its NG2500-class vessels that will generate between approximately $11.6M-$14.3M of revenue in 2022. In addition, the Company announced on December 27, 2021, that the Seajacks Scylla, another vessel of Seajacks UK limited, signed a contract with Van Oord for employment in Europe in 2023. The firm charter duration of the contract will generate approximately $60.0M of revenue from the Q1 through the Q4 of 2023.

06:10 EST Energy Vault, Atlas Renewable, China Tianying announce $100M transaction - Energy Vault announced a License and Royalty agreement for renewable energy storage with Atlas Renewable and their majority investor China Tianying. The agreement supports the deployment of Energy Vault's proprietary gravity energy storage technology and energy management software platform within mainland China and the Special Administrative Regions of Hong Kong and Macau. In addition, Atlas Renewable is making a $50M investment to upsize the current private placement investment from $150M to $200M, and paying an additional $50M in 2022 licensing fees for use and deployment of Energy Vault's gravity energy storage technology. In conjunction with its previously announced business combination with Novus Capital Corporation II, Energy Vault announced this private placement investment. In addition to the strategic partnership and licensing agreement announced today, Atlas Renewable has executed a subscription agreement committing a $50M investment to Novus's PIPE.

06:07 EST Stanley Black & Decker to begin $4B share repurchase program in Q1 - The company said, "Approximately $4 Billion Share Repurchase Program Is Expected To Be Executed In 2022 With $2.0 - $2.5 Billion Expected To Occur In The First Quarter."

06:02 EST UPS declares quarterly dividend of $1.52 per share, up 49% y/y - UPS will pay a first-quarter 2022 dividend of $1.52 per share on all outstanding Class A and Class B shares. The dividend is payable March 10 to shareowners of record on February 22.

05:35 EST Arthur J. Gallagher acquires Devitt Insurance Services - Arthur J. Gallagher announced the acquisition of Romford, Essex-based Devitt Insurance Services in the United Kingdom. Terms of the transaction were not disclosed. Founded in 1936, Devitt is a privately owned retail property/casualty insurance broker predominantly focusing on coverages for motorcycles and motorhomes. It serves approximately 130,000 customers through a team of 130 colleagues. William Hughes, Tony Chapman and their associates will continue to operate from their current locations in Romford and Ipswich, Suffolk, under the direction of SME and personal lines managing director Gareth Birch.

05:30 EST MSA Safety to expand European shared services in Poland - MSA Safety announced it has reached an agreement with the company's Berlin Works Council to transition 64 support positions from Berlin, Germany to the company's European Shared Services Center, or SSC, in Warsaw, Poland. MSA expects to continue to maintain a strong presence in Germany, primarily involved in the research and product development, manufacturing and sales of advanced safety technologies.

05:21 EST NIO delivers 9,652 vehicles in January - NIO announced its January delivery results. NIO delivered 9,652 vehicles in January, representing an increase of 33.6% year-over-year. The deliveries consisted of 1,531 ES8s, the company's six- or seven-seater flagship premium smart electric SUV, 5,247 ES6s, the company's five-seater high-performance premium smart electric SUV, and 2,874 EC6s, the company's five-seater premium smart electric coupe SUV. As of January 31, cumulative deliveries of the ES8, ES6 and EC6 reached 176,722 vehicles. In January, the company released Aspen 3.0.5 NO, which is exclusively developed for Norway, to users in the local market, marking its first firmware over-the-air update outside of China. Aspen is the smart operating system of NIO vehicles based on NIO Technology Platform 1.0. As of January 31, NIO has pushed FOTA updates to its users for over 1.3M times cumulatively, releasing 199 new features and 401 enhancements. In addition, the company has been accelerating the deployment of its power, sales and service network. As of January 31, NIO has built 836 Power Swap stations, 3,766 Power Chargers and 3,656 destination chargers, and opened 42 NIO Houses, 341 NIO Spaces, 55 NIO Service Centers and 180 authorized service centers across China.

05:16 EST Li Auto delivers 12,268 Li ONEs in January - Li Auto announced that the company delivered 12,268 Li ONEs in January, representing a 128.1% increase year over year. The cumulative deliveries of Li ONE reached 136,356 since the vehicle's market debut. "Li Auto would like to wish everyone a happy Chinese New Year. I am very pleased, on such a day, to share with you the exciting news that we have delivered over 10,000 Li ONEs for the third consecutive month, achieving a new record for domestic branded premium vehicles priced above RMB300,000 in China. This accomplishment comes from our users' recognition, and we deeply appreciate their continued support. During a recent third-party Autonomous Emergency Braking (AEB) test, Li ONE was ranked No. 1 and was the only assessed model capable of accurately identifying crossing vehicles and two-wheelers, demonstrating our strong ADAS research and development capabilities. So far, more than 70,000 users have enjoyed a safer and easier driving experience enabled by our full-stack self-developed NOA. Looking ahead, we will remain committed to investing in research and development to provide our users with products and services that offer greater safety, convenience, and comfort," said Yanan Shen, co-founder and president of Li Auto. As of January 31, the company had 220 retail stores in 105 cities, as well as 276 servicing centers and Li Auto-authorized body and paint shops operating in 204 cities.

05:12 EST Xpeng delivers 12,922 Smart EVs in January - XPeng announced its vehicle delivery results for January. XPeng delivered 12,922 Smart EVs in January, representing a 115% increase year-over-year, exceeding the monthly delivery benchmark of 10,000 units for the fifth consecutive month. Deliveries in January consisted of 6,707 P7 smart sports sedans, representing an 81% increase year-over-year. 4,029 P5 smart family sedans were delivered in January, bringing total deliveries to over 11,000 since its launch in September 2021. Also, 2,186 G3 and G3i smart compact SUVs were delivered in January. As of January 31, the company's cumulative Smart EV deliveries surpassed 150,000. XPeng is carrying out a technology upgrade at its Zhaoqing plant, taking advantage of the scheduled production downtime over the Chinese New Year Holiday starting at the end of January to early February. The upgrade will enable accelerated delivery of the significant order backlog carried over from 2021 as well as allow the company to better serve the increasing demand in the new year. XPeng continues to rapidly expand its network in China. XPeng provided fast and reliable charging services to customers at 813 branded supercharging stations across 333 Chinese cities since January 17.

05:06 EST Kratos Defense, Kymeta partner to develop antenna technologies - Kymeta and Kratos Defense announced a strategic partnership to jointly develop products and solutions that will enable modern, virtualized ground systems to better leverage the capabilities of next generation mobile satellite antennas. Among the broader goals of the partnership are to advance the ability of ground systems to support, leverage, manage, and control electronically-steered and multi-purpose antennas to better support the capabilities of software-defined and multi-beam satellites. This effort will initially focus on joint development of a software-defined remote terminal that will support a variety of dynamic satellite connectivity applications, including support for multi-orbit use cases where connectivity to LEO, MEO, and GEO satellites through the same antenna are desirable.